Skip to main content
OpenTrials
Completed

NCT Number: NCT05445206

Clinical Validation Study for CPM Device

This study is designed to be a clinical validation study to ready the CPM System for FDA 510(k) submission. This study will be conducted as a prospective non-randomized. The study is non-significant risk since the CPM Device is noninterventional and noninvasive. The study is primarily designed to validate the accuracy of the respiration rate and the changes in relative tidal volume. All participants will be fitted with both the CPM Device as well as reference devices (capnography and ECG). Participants will be randomized between 4 procedures (A-D) which will determine the order of 18 exercises. Each exercise has about 2 minutes of device recording and two minutes of rest. Each exercise contains two positions: sitting up for one minute and lying down for one minute. For some exercises, the participant will be instructed to breathe at a certain rate (assisted by a metronome). For other exercises, the participants will breathe at a normal rate but change how deep the are breathing. For exercise 18, all capnography reference devices will be removed, and an ECG reference device will be placed. After exercise 18, the participant will have all devices removed and the study visit will terminate. The participant will receive a safety follow-up call about 1 week after their visit.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure Cardiovascular Diseases Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic Hospital

Rochester, Minnesota, 55905-0001, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults over the age of 18 and who are willing and able to give informed consent
  • Willing and able to participate in all activities related to this study, including trimming chest hair and wearing a reference device and the CPM wearable device
  • Volunteers of any race, any gender
  • Range of physiques
  • Healthy

Exclusion criteria

  • Injury or skin disturbance in the area of the test device
  • Allergies or sensitivities to silicone/acrylic-based adhesive
  • Pregnant, method of assessment at discretion of PI
  • Currently smokes cigarettes
  • Has known respiratory conditions that might prevent them from following the study procedure such as:
  • Flu
  • Pneumonia/bronchitis
  • Shortness of breath/respiratory distress
  • Respiratory or lung surgery
  • Emphysema, COPD, lung disease
  • Has self-reported heart or cardiovascular conditions such as chest pain, AFib, CHF, cardiomyopathy, or other conditions that could interfere with cardiopulmonary function
  • Has other self-reported health conditions that could interfere with the breathing patterns and exercises detailed in the protocol (including wearing a capnography mask)

Treatment and study plan

CardioPulmonary Management Device (CPM)

Device

CPM device is used in tangent with reference capnography device.

Primary outcomes

  1. Accuracy of CPM System Calculated RR Versus Reference Device Via Percent of Error Accuracy of Respiration Rate

    Time frame: up to 3 hours

    Accuracy of CPM System calculated RR versus reference device reported as percentage of respiration rate error within +/- breath rates per minute. Acceptance for clinical utility is >= 85%. Percentage of respiration rate error within ± 2bpm. Acceptance criteria for clinical utility is >= 85%. The percentage of respiration rate within ± 2brpm was calculated by data points, regardless of its rate and breathing condition, which the CPM System did not screen, therefore reporting the numeric values. Each data point will produce binary result (True or False) if the error is within ± 2 brpm. Assuming this binary result follows a binominal distribution, its confidence interval is also calculated.

  2. Root Mean Squared Error (RMSE) of Respiration Rates From the CPM System vs Reference Device for Metronome Guided Breathing and Non-metronome Guided Breathing.

    Time frame: up to 3 hours

    Root mean square (RMS) of residual relative error of relative tidal volume. Acceptance criteria for clinical utility is <= 35%. First, the subject-specific linear fitting is performed after taking the natural log of both CPM's rTV and reference TV. Then, the residual errors in rTV after the fitting were calculated. Finally, all subject's residual errors are pooled together to calculate the root mean squared (RMS) residual relative errors. The confidence interval was calculated assuming the square of this error follows Chi-square distribution. This error characterized in a log-log domain is converted back to characterize a relative accuracy by taking an exponential of natural constant followed by subtraction of one. The RMS of residual error in % is characterized in this way because the linear fitting in the log-log domain and its residual errors represents faithful relative residual error regardless of an absolute value of TV.

Secondary outcomes

  1. Accuracy of CPM System Calculated Respiration Rate Versus Reference Device, Reported as Root Mean Squared (RMS) Error

    Time frame: up to 3 hours

    Accuracy of CPM System calculated RR versus reference device. It is reported in Root Mean Squared error for both exercises with metronome guided breathing and non-metronome guided breathing. Acceptance criteria of substantial equivalence is ~1.6 breath rates per minute (BRPM) for metronome guided breathing and 3.0 BRPM for non-metronome guided breathing.

  2. CPM's ECG Metrics Compared to Reference Device Lead II ECG Metrics (Results Displayed as % Comparasion)

    Time frame: up to 3 hours

    Test the CPM System ECG strip against a lead II ECG strip. Results are displayed as % of CPM strips equivalent to Lead II ECG strips. One CPM ECG strip and one reference lead II strip were analyzed per patient.

  3. Test Device Skin Temperature vs Reference Device Skin Temperature Comparison

    Time frame: up to 3 hours

    The accuracy is characterized as mean error across all measurement items and all subjects.

Sponsors and collaborators

Lead sponsor

Analog Device, Inc.

Other

Collaborators

  • Mayo Clinic

Registry information

Official study title

Clinical Validation Study for Noninvasive Cardiopulmonary Management Device (Phase II)

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Jul 6, 2022
Registry last updated
Jun 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.